| Title: |
The impact of COVID-19 on familial Mediterranean fever: a nationwide study. |
| Authors: |
Günendi, Zafer, Yurdakul, Fatma Gül, Bodur, Hatice, Cengiz, Ahmet Kıvanç, Uçar, Ülkü, Çay, Hasan Fatih, Şen, Nesrin, Keskin, Yaşar, Gürer, Gülcan, Melikoğlu, Meltem Alkan, Altıntaş, Duygu, Deveci, Hülya, Baykul, Merve, Nas, Kemal, Çevik, Remzi, Karahan, Ali Yavuz, Toprak, Murat, Ketenci, Sertaç, Nayimoğlu, Mehmet, Sezer, İlhan |
| Source: |
Rheumatology International; Aug2021, Vol. 41 Issue 8, p1447-1455, 9p |
| Subject Terms: |
FAMILIAL Mediterranean fever, COVID-19, COMPUTED tomography, ADULT respiratory distress syndrome, COVID-19 testing |
| Abstract: |
The study aimed to evaluate the impact of the coronavirus disease 2019 (COVID-19) in patients with familial Mediterranean fever (FMF) and to assess the relationships between FMF characteristics and severe COVID-19 outcomes such as hospitalization. The study was planned within a national network of 21 different centers. Demographics, FMF-related clinical and genetic characteristics, and COVID-19 outcomes were obtained. A total of 822 patients with FMF (mean age of 36 years) were included in the study. Fifty-nine of them (7%) had a COVID-19 diagnosis confirmed by real-time PCR test or chest CT findings. Most FMF patients with COVID-19 (58) had mild and moderate disease activity. All patients were on colchicine treatment. However, 8 of them (13.6%) were not compliant with colchicine use and 9 of them (15.3%) were colchicine resistant. Twelve FMF patients with COVID-19 were hospitalized. There were 4 patients requiring oxygen support. COVID-19 related complications were observed in 2 patients (1 thromboembolism, 1 acute respiratory distress syndrome). Hospitalized COVID-19 patients with FMF were older than non-hospitalized patients (median ages: 51 and 31 years, respectively; p: 0.002). Other FMF-related characteristics were similar between the groups. FMF-related characteristics were not found to be associated with poor outcomes in COVID-19. Thus, FMF may not be a risk factor for poor COVID-19 outcomes. [ABSTRACT FROM AUTHOR] |
|
Copyright of Rheumatology International is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
